KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis

Am J Kidney Dis. 2013 Sep;62(3):403-41. doi: 10.1053/j.ajkd.2013.06.002. Epub 2013 Jul 18.


Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all ages throughout the world. Because these disorders are relatively rare, it is difficult to perform randomized clinical trials to define optimal treatment for many of the specific glomerulopathies. In the absence of high-grade evidence to guide the care of glomerular diseases, in June 2012, KDIGO (Kidney Disease: Improving Global Outcomes) published an international clinical guideline for GN. The Work Group report represents an important review of the literature in this area and offers valid and useful guidelines for the most common situations that arise in the management of patients with glomerular disease. This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the GN guideline into the context of the US health care system. Overall, we support the vast majority of the recommendations and highlight select areas in which epidemiological factors and medical practice patterns in this country justify modifications and adjustments in order to achieve favorable outcomes. There remain large gaps in our knowledge of the best approaches to treat glomerular disease and we strongly endorse an expanded clinical research effort to improve the health and long-term outcomes of children and adults with GN.

Publication types

  • Review

MeSH terms

  • Glomerulonephritis / diagnosis*
  • Glomerulonephritis / epidemiology
  • Glomerulonephritis / therapy*
  • Humans
  • Practice Guidelines as Topic / standards*
  • Randomized Controlled Trials as Topic / methods
  • Randomized Controlled Trials as Topic / standards
  • Research Report / standards*
  • United States